NRP1 and pancreatic ductal adenocarcinoma: Blocking the interaction between VEGF165 and NRP1 with an anti‐NRP1 heptapeptide A7R (ATWLPPR), significantly reduced VEGFR signaling and tumor growth in a pancreatic ductal adenocarcinoma mouse model (Zhou et al., 2016).